XNYS · Healthcare · Drug Manufacturers - General
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Q1 2026 | 2.66 | 2.65 | -0.38% | $15.00B | ❌ Miss | +0.21% | +0.56% | +6.78% |
| 2026-02-04 | Q4 2025 | 2.66 | 2.71 | +1.88% | $16.62B | ✅ Beat | +0.03% | +1.74% | +5.99% |
| 2025-10-31 |
| Q3 2025 |
| 1.78 |
| 1.86 |
| +4.49% |
| $15.78B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-31 | Q2 2025 | 2.90 | 2.97 | +2.41% | $15.42B | ✅ Beat | — | — | — |
| 2025-04-25 | Q1 2025 | 2.38 | 2.46 | +3.36% | $13.34B | ✅ Beat | — | — | — |
| 2025-01-31 | Q4 2024 | 2.26 | 2.16 | -4.42% | $15.10B | ❌ Miss | — | — | — |
| 2024-10-30 | Q3 2024 | 2.92 | 3.00 | +2.74% | $14.46B | ✅ Beat | — | — | — |
| 2024-07-25 | Q2 2024 | 2.57 | 2.65 | +3.11% | $14.46B | ✅ Beat | — | — | — |
Showing last 8 quarters.